Ethylene regulates numerous aspects of plant growth and development. Multiple external and internal factors coordinate ethylene production in plant tissues. Transcriptional and post-translational regulations of ACC synthases (ACSs), which are key enzymes mediating a rate-limiting step in ethylene biosynthesis have been well characterized. However, the regulation and physiological roles of ACC oxidases (ACOs) that catalyze the final step of ethylene biosynthesis are largely unknown in Arabidopsis. Here, we show that Arabidopsis exhibits a tissue-specific expression pattern that is regulated by multiple signals, and plays roles in the lateral root development in Arabidopsis. Histochemical analysis of the promoter indicated that expression was largely modulated by light and plant hormones in a tissue-specific manner. We demonstrated that point mutations in two E-box motifs on the promoter reduce the light-regulated expression patterns of . The mutant showed reduced ethylene production in root tips compared to wild-type. In addition, displayed altered lateral root formation. Our results suggest that Arabidopsis ACO1 integrates various signals into the ethylene biosynthesis that is required for ACO1's intrinsic roles in root physiology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199567PMC
http://dx.doi.org/10.14348/molcells.2018.0092DOI Listing

Publication Analysis

Top Keywords

ethylene biosynthesis
16
multiple signals
8
root development
8
ethylene production
8
step ethylene
8
lateral root
8
ethylene
7
arabidopsis
5
root
5
arabidopsis acc
4

Similar Publications

Background: Data-driven disease progression models of Alzheimer's disease (AD) have identified subtypes in regional patterns of Aβ deposition using amyloid PET. In addition to Aβ accumulation, early frame measures of tracer delivery from amyloid PET are strongly correlated with blood flow. This work explores whether combining tracer delivery with amyloid binding measures can improve the subtype and stage characterisation over amyloid binding alone.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Individuals from diverse racial and ethnic groups are severely underrepresented in AD trials in part due to disproportionate biomarker ineligibility. Evidence from recent studies support plasma phosphorylated tau (P-tau217) as an early marker for brain Aβ pathology and a reliable marker in predicting elevated brain amyloid PET in cognitively unimpaired adults. We examined the relationship between P-tau217 and florbetapir PET standard uptake value ratios (SUVR) by self-reported racial and ethnic groups in preclinical AD studies.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Center for Alzheimer's Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Background: Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial (NCT02008357), including cognitively unimpaired participants with brain amyloid pathology on florbetapir F 18, demonstrates that levels of plasma P-tau217, as detected by an electrochemiluminescence (ECL) immunoassay, is strong predictor of elevated cerebral amyloid on florbetapir PET in cognitively unimpaired individuals. Here we compare plasma P-tau217 measures over 12 weeks using a P-tau217 ECL immunoassay.

Method: A4 trial placebo-group participants who had their first baseline and first post-baseline plasma P-tau217 samples collected within 175 days of each other were included in these analyses.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Mallinckrodt Institute of Radiology, Washington University School of Medicine in St Louis, St Louis, MO, USA.

Background: Differences in amyloid PET radiotracer pharmacokinetics and binding properties lead to discrepancies in amyloid uptake measurements, which may adversely affect the statistical power of clinical trials that utilize multiple tracers to track brain amyloid deposition. To address this, Centiloid was developed for standardizing global amyloid SUVRs across tracers to a common scale. Alternatively, ComBat is a technique for harmonizing batch effects while preserving variations from biologically-relevant covariates.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

University of Science and Technology of China, Hefei, Anhui, China.

Background: The exact impacts of β-site APP cleaving enzyme (BACE1) on brain atrophy and cognitive decline in the Alzheimer's disease (AD) remain not fully understood. This study aimed to investigate the relationship between BACE1 in cerebrospinal fluid (CSF) and amyloid-β (Aβ) pathology, neurodegeneration and cognitive function.

Method: This study involved 359 participants from original individuals of the China Aging and Neurodegenerative Disorder Initiative (CANDI) cohort, who underwent measurements of AD biomarkers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!